Is Moderna a Buy After Its Earnings Disappointment?
Moderna (NASDAQ: MRNA) has been a sure bet for most of the past year and a half. The company brought its coronavirus vaccine from early development to market in about nine months. And the product has been generating billions of dollars in revenue -- and profit -- ever since. As a result, the shares have soared. Last year, they climbed 434%. And this year, they gained 230% right up until Moderna's third-quarter earnings report this past week.
Then, in two days, the stock tumbled 33%. That's after Moderna lowered its forecast for vaccine sales this year. Now the question is this: Is this a golden opportunity to buy the stock? Or is Moderna's stock market success story over? Let's find out.
Image source: Getty Images.
Source Fool.com
